SLActive®

Surface innovation

For years, implants with the SLA® surface have delivered excellent results and high implant success rates.1 We followed this significant development in implant dentistry with the SLActive® surface, the next generation in surface technology. Designed to promote faster osseointegration and to provide higher predictability, SLActive® has become a central feature in the Straumann® Dental Implant System.

The SLActive® surface is designed for:

Faster osseointegration for every indication1,3,4,5,6,7,8,9

SLActive® is designed to deliver higher security and has shown more predictability in early treatment giving you confidence in the treatment outcome.

  • In the osseointegration process, two factors play an important role: Primary stability (mechanical stability) and secondary stability (biologic stability after bone remodeling) of the implant in the bone. With conventional surfaces, implants are exposed to a higher risk of failure due to an overall stability dip between weeks two to four.
  • SLActive® reduces the risk during the critical early treatment by accelerating and optimizing implant integration. The bone formation process is initiated at an earlier stage, resulting in radically improved implant stability in the ‘critical dip’ period.

The optimized osseointegration process with SLActive® leads to a higher implant stability between week 2 and 4

  1. Primary stability (green line)
    As soon as an implant is placed into the jawbone, certain areas of the implant surface are in direct contact with the bone. This contact is called primary or mechanical stability and depends on implant shape, bone quality and implant bed preparation. The primary stability gradually decreases in the bone remodeling process.
  2. Secondary stability (blue line)
    In the healing process, the bone is remodeled and forms new contact areas with the implant surface. This new bone contact is called secondary or biological stability. When the healing process is complete, the initial mechanical stability is fully replaced by biological stability.
  3. Total stability (orange line)
    The sum of primary and secondary stability is referred to as total stability.

Reduced healing times from 6–8 weeks down to 3–4 weeks2

Most implant failures occur in the critical early period between week 2 and 4. SLActive® is designed to deliver higher security and has shown more predictability in early treatment, giving you confidence in the treatment outcome. Immediate and early loading with Straumann® SLActive implants yields excellent survival rates (98 % and 97 % after 1 year).*

SLActive® has been developed to optimize early implant stability and to reduce the risk during the critical early treatment. Animal test results show that SLActive® has 60 % more bone-to-implant contact*** compared to SLA® after 2 weeks**. For the challenges in daily practice, SLActive® offers higher treatment predictability and security for clinicians and patients.

The decreasing primary stability and increasing secondary stability result in a decrease in overall stability (dip) between week 2 and 4 after implant placement.

The optimized osseointegration process with SLActive® leads to a higher implant stability between week 2 and 4

* J. Ganeles et al. Immediate and early non-occlusal loading of Straumann® implants with SLActive® surface: 1 year results from a prospective multicenter randomized-controlled study. Clin. Oral Impl. Res. 2008;19:1119-1128.
** Raghavendra et al. Early wound healing around endosseous implants: a review of the literature. Int J Oral Maxillofac Implants. 2005 May-Jun;20(3):425-31.
*** D. Buser et al. Enhanced bone apposition to a chemically advanced SLA® titanium surface. 07/2004, JDR 83 (7): 529 – 533, 2004.

Higher treatment predictability

First human histological proof of SLActive® benefits*

Although similar healing patterns were observed for both SLA® and SLActive® implants, bone-to-implant contact (BIC) was greater after 14 days and significantly greater after 28 days for SLActive®.

This substantially higher BIC-value results in improved treatment predictability and helps to minimize the potential for early implant failures.

Confidence in challenging protocols

Most implant failures occur in the critical early period between weeks 2 and 4.** SLActive® is designed to deliver higher security and has shown more predictability in early treatments, giving you confidence in the treatment outcome. Immediate and early loading with Straumann® SLActive® implants yields excellent survival rates of respectively 96.9 % and 96.7 % after 3 years.***

Bone crest stability in critical protocols. After 3-year follow-up visit no significant change in the proximal bone crest level of the SLActive® interface from implant placement.

* Lang, N. P., et al. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants.Res 22.4 (2011): 349-56.
** Raghavendra, S., M. C. Wood, and T. D. Taylor. Early wound healing around endosseous implants: a review of the literature. Int.J Oral Maxillofac.Implants 20.3 (2005): 425-31.
*** Nicolau, P., et al. Immediate and Early Loading of Chemically Modified Implants in Posterior Jaws: 3-Year Results from a Prospective Randomized Multicenter Study. Clin.Implant.Dent.Relat Res. (2011).

All our Roxolid® implants are also equipped with the SLActive® surface, resulting in higher tensile strength combined with excellent osseointegration properties.


1 Bornstein MM, Wittneben JG, Brägger U, Buser D. Early loading at 21 days of non-submerged titanium implants with a chemically modified sandblasted and acid-etched surface: 3-year results of a prospective study in the posterior mandible. J. Periodontol. 2010 Jun;81(6):809–18.
2 Oates TW, Valderrama P, Bischof M, Nedir R, Jones A, Simpson J, Toutenburg H, Cochran DL. Enhanced implant stability with a chemically modified SLA® surface: a randomized pilot study. Int. J. Oral Maxillofac. Implants. 2007;22(5):755–760.
3 Schwarz F, Herten M, Sager M, Wieland M, Dard M,BeckerJ. Bone regeneration in dehiscence-type defects at chemically modified (SLActive) and conventional SLA titanium implants: A pilot study in dogs. J. Clin. Periodontol. 2007;34(1):78–86.
4 Schwarz F, Ferrari D, Herten M, Mihatovic I, Wieland M, Sager M, Becker J. Effects of surface hydrophilicity and microtopography on early stages of soft and hard tissue integration at non-submerged titanium implants: An immunohistochemical study in dogs. J. Periodontol. 2007;78(11):2171–2184.
5 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of initial and early subepithelial connective tissue attachment at chemicallymodified and conventional SLA® titanium implants. A pilot study in dogs. Clin. Oral Impl. Res. 2007;11(3):245–455.
6 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of initial and early osseous integration at chemically modified and conventional SLA® titanium implants: Preliminary results of a pilot study in dogs. Clin. Oral Impl. Res. 2007;11(4):481–488.
7 Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann B, Lussi A, Steinemann SG. Enhanced bone apposition to a chemically modified SLA titanium surface. J. Dent. Res. 2004 Jul;83(7):529–33.
8 Ganeles J, Zöllner A, Jackowski J, ten Bruggenkate C, Beagle J, Guerra F. Immediate and early loading of Straumann implants with a chemically modified surface (SLActive®) in the posterior mandible and maxilla: 1-year results from a prospective multicenter study. Clin. Oral Impl. Res. 2008;19:1119–1128.
9 Luongo G, Oteri G. A noninterventional study documenting use and success of implants with a new chemically modified titanium surface in daily dental practice. J. Oral Implantol. 2010;36(4):305–14.